Compare MOVE & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOVE | DMRA |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2021 | 2020 |
| Metric | MOVE | DMRA |
|---|---|---|
| Price | $21.43 | $23.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $43.00 |
| AVG Volume (30 Days) | 39.1K | ★ 391.2K |
| Earning Date | 04-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $433,000.00 | N/A |
| Revenue This Year | $1,460.71 | N/A |
| Revenue Next Year | $96.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $16.50 |
| 52 Week High | $34.87 | $28.76 |
| Indicator | MOVE | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 54.63 |
| Support Level | $6.27 | $22.71 |
| Resistance Level | $25.90 | $27.70 |
| Average True Range (ATR) | 2.21 | 2.10 |
| MACD | 0.08 | 0.33 |
| Stochastic Oscillator | 57.33 | 70.73 |
Corvex Inc is an AI cloud computing company that provides computing infrastructure for artificial intelligence workloads, including GPU-accelerated computing, confidential computing, and inference services. Its offerings are used by government and enterprise customers, including those with regulated workloads, to support the deployment and operation of AI models and data processing systems. The company generates revenue from the sale of Wellness Rings, portable chargers and charging cables, ring sizers, and mobile applications.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.